Objectives: The discovery of mobile colistin resistance mcr-1, a plasmid-borne polymyxin resistance gene, highlights the potential for widespread resistance to the last-line polymyxins. In the present study, we investigated the impact of mcr-1 acquisition on polymyxin resistance and biological fitness in Klebsiella pneumoniae.
Introduction
The spread of MDR amongst Gram-negative bacteria has emerged as one of the most serious global public health threats. 1 Owing to the paucity of newly approved antibiotics with novel modes of action, polymyxins (i.e. colistin and polymyxin B) have been increasingly used for treating MDR Gram-negative bacterial infections. 2 However, in recent times, there have been increasing reports of polymyxin-resistant Gram-negative bacterial infections in patients and animals. [3] [4] [5] [6] [7] [8] The primary mechanism of polymyxin resistance in Gram-negative bacteria involves modification of lipid A with positively charged residues, such as aminoarabinose or phosphoethanolamine (pEtN). 9, 10 These modifications diminish the interaction of polymyxin molecules with the outer membrane, leading to resistance. 11 Modifications to the glucosamine phosphate groups of lipid A are usually mediated by chromosomal mutation, resulting in up-regulation of two-component systems, PhoP/PhoQ and PmrA/PmrB. 12, 13 The inactivation of the mgrB gene, a negative regulator of the PhoP/PhoQ system, has been shown to play a key role in polymyxin resistance in Klebsiella pneumoniae.
14,15
The first plasmid-borne polymyxin resistance gene, mcr-1, was detected in a livestock isolate in China in November 2015. 16 Subsequently, several variants of the mcr genes (mcr-1 to -5) have been reported in a number of countries. [17] [18] [19] [20] [21] [22] [23] The mcr gene has been identified globally in various Gram-negative bacteria isolated from animals, meat, processed meat products, vegetables and humans. 24, 25 The mcr gene encodes a pEtN transferase that modifies the negative phosphate groups of lipid A with positively charged pEtN residues. 16 This readily transferable polymyxin resistance gene holds the potential to rapidly spread resistance. Escherichia coli remains as the most prevalent Gram-negative bacterium harbouring the mcr gene, whereas lower prevalence is observed in K. pneumoniae; however, the latter pathogen is a leading cause of nosocomial infections globally. 26, 27 The mcr-1 gene is believed to have originated from animalassociated bacteria. It has been frequently isolated from livestock and is supposedly sustained by the heavy usage of colistin in the agricultural and veterinary sectors. 16, 28 This hypothesis is supported by the identification of the earliest mcr-1-harbouring E. coli strain isolated from farm chickens in the 1980s, which coincides with the onset of colistin use in poultry farming in China. 29 Purportedly, the heavy usage of colistin in Chinese agriculture may have acted as the selective pressure that promoted the spread and evolution of mcr-1-mediated resistance. Although the prevalence of mcr-1 in bacteria isolated from human sources is not as high as that from animals, the zoonotic potential of mcr-1-carrying bacteria has been indicated by a number of studies. 28, 30, 31 Zoonotic infections by bacteria carrying mcr-1 highlight the urgent need to limit the use of colistin in agriculture and veterinary practices. Fortunately, the use of colistin in animal feed was banned in China soon after the increasing reports of mcr-1.
32
The development of antibiotic resistance often comes with a cost to biological fitness, defined by reduced competitive ability in an antibiotic-free environment, a phenomenon that usually allows the fitter, often susceptible, strain to outcompete the resistant strain. 33 The primary aim of the present study was to investigate the potential fitness cost incurred by mcr-1 in K. pneumoniae.
Materials and methods

Bacterial strains and plasmids
K. pneumoniae B5055 (K2:O1) was employed as the parental strain for this study and E. coli JW1 was used as a reference strain for the in vitro biological fitness assays. 34 The codon-optimized mcr-1 gene was synthesized by Invitrogen TM GeneArt
TM . An mcr-1 recombinant plasmid (pmcr-1) was constructed by ligating mcr-1 into the low-copy, broad-host-range vector pBBR1MCS-5 at the XhoI and HindIII sites using T4 DNA ligase (New England BioLabs). 35 The vector (pBBR1MCS-5) and mcr-1 recombinant plasmid (pmcr-1) were isolated using a QIAprep V R Spin Miniprep kit and transformed into K. pneumoniae B5055 by electroporation conducted using a 0.1 cm electroporation cuvette with MicroPulser (Bio-Rad) at the EC1 setting (1.8 kV). Cells were recovered in LB broth for 1 h, followed by plating on LB agar with 20 mg/L gentamicin (Sigma-Aldrich). Successful transformants were confirmed by PCR and Sanger sequencing using M13 Fw (5 0 -GTAAAACGACGGCCAGT-3 0 ) and M13 Rv (5 0 -AACAGCTATGACCATG-3 0 ) primers (Micromon, Monash University). Unless otherwise stated, K. pneumoniae B5055 pBBR1MCS-5 and K. pneumoniae B5055 pmcr-1 were grown in LB broth supplemented with 20 mg/L gentamicin and E. coli JW1 was supplemented with 50 mg/L ampicillin (Sigma-Aldrich).
In vitro polymyxin B susceptibility
MICs of polymyxin B were determined using broth microdilution in CAMHB (Oxoid). 36 Polymyxin B (Beta Pharma) was tested over 0.125-128 mg/L and gentamicin (final concentration of 20 mg/L) was added to the growth medium of the plasmid-carrying strains as required.
Plasmid stability
A conventional plate count method was employed to examine the stability of the vector and mcr-1 recombinant plasmid in K. pneumoniae strain B5055. Briefly, cultures were grown at 37 C in a shaking water bath (200 rpm) and serially passaged for 10 consecutive days with 1:1000 dilution in antibiotic-free LB broth, allowing 10 cell generations per day. Samples were taken each day, serially diluted and plated on antibiotic-free LB agar. After incubation overnight, 100 colonies were randomly selected and patched onto gentamicin-containing and antibiotic-free LB agar plates. The percentage of plasmid retention was calculated by dividing the number of colonies on gentamicin-containing LB agar by the total number of colonies patched. Three biological replicates were included for each group.
Extraction and structural analysis of lipid A
Lipid A was extracted from K. pneumoniae B5055 using a mild acid hydrolysis method. 37 In brief, bacterial culture at an OD 600 of 0.8 was collected by centrifugation at 9600 g and washed twice with PBS (pH 7.4). The cells were resuspended in PBS, followed by addition of chloroform and methanol to form a single-phase Bligh-Dyer mixture (water/chloroform/ methanol, 0.8:1:2, v/v). LPS was pelleted by centrifugation at 3220 g and washed once with single-phase Bligh-Dyer mixture. The pellet was then resuspended in hydrolysis buffer [50 mM sodium acetate (pH 4.5)/1% SDS], followed by sonication and incubation in boiling water for 45 min to ensure complete hydrolysis. The solution was converted into a two-phase Bligh-Dyer mixture with addition of chloroform and methanol to form a final mixture of water/chloroform/methanol (0.9:1:1, v/v). Following centrifugation at 3220 g, the lower phase containing lipid A was extracted and allowed to dry overnight. For LC-MS analysis, the dried lipid A was reconstituted in chloroform/methanol (1:1, v/v) and the supernatant was collected into a glass LC-MS vial after centrifugation at 14000 g. The structure of lipid A was analysed using a Q-Exactive Hybrid QuadrupoleOrbitrap Mass Spectrometer (Thermo Scientific).
In vitro biological fitness assay
The fitness of K. pneumoniae strains was measured in competition against the reference strain E. coli JW1. Bacteria were inoculated into sterile filtered M9 minimal medium supplemented with antibiotics as appropriate. 38 Overnight cultures were pelleted and washed with PBS prior to resuspension in fresh M9 minimal medium. An equal volume (1 mL) of the experimental strain and reference strain at 10 9 cfu/mL was mixed by vortexing. The mixed bacterial culture was diluted 1:100 in fresh M9 minimal medium and incubated for 24 h, which permitted 6.6 cell generations. Samples at 0 and 24 h were diluted 1:100 in PBS and analysed using flow cytometry. The experimental and reference strains were analysed using the dot plot of side scatter (SSC) versus forward scatter (FSC), in which gates were placed around the two populations, which were distinguishable based on morphological differences between the experimental and reference strains. The strains belonging to the populations gated were identified by referring to the single experimental and reference strain control. The selection coefficients were determined based on the following regression model: selection coefficient " [ln(E/R) t # ln(E/R) 0 ]/T, where E/R is the ratio of cell numbers of the experimental to the reference strain and T is the generation number. 39 All calculated selection coefficients were normalized to set the K. pneumoniae B5055 parental strain as zero by subtracting the mean selection coefficient of the parental strain. Four biological replicates were included for each sample. Data were analysed using the non-parametric Mann-Whitney U-test (GraphPad Prism software).
In vivo effect of mcr-1 in a neutropenic mouse thigh infection model 40 Early logarithmic-phase K. pneumoniae strains (1%10 5 cfu/mL)
were introduced intramuscularly into each posterior thigh muscle to establish thigh infection and two mice were included in each group (i.e. four thighs). At 2 h after inoculation, polymyxin B was administered subcutaneously at 10 mg/kg every 8 h (total dose of 30 mg/kg/day) to the treatment group. Mice were euthanized at 24 h and both thighs were harvested, followed by homogenization with saline and filtration using a sterile filter bag (pore size 280 lm) for viable counting. The agar plates were incubated overnight at 37 C and the number of cfu of bacteria per thigh was determined. Data were analysed using the non-parametric Mann-Whitney U-test.
Results
Prior to commencing our phenotypic investigation, we confirmed the presence of the vector (pBBR1MCS-5) and mcr-1 recombinant plasmid (pmcr-1) in K. pneumoniae B5055 with PCR using M13-specific forward and reverse primers. Comparison of the vector and mcr-1 recombinant plasmid confirmed the presence of a 1635 bp insertion in pBBR1MCS-5 and the insert was confirmed with Sanger sequencing.
Contribution of mcr-1 to polymyxin resistance and plasmid stability
To evaluate the intrinsic resistance of the K. pneumoniae B5055 parental strain and the contribution of mcr-1 to polymyxin resistance, we first sought to determine their respective MICs. The K. pneumoniae B5055 parental strain, vector-only K. pneumoniae B5055 pBBR1MCS-5 strain and mcr-1-expressing K. pneumoniae B5055 pmcr-1 strain displayed MICs of 1, 0.5 and 4 mg/L, respectively. The stabilities of the mcr-1 recombinant plasmid and the vector in K. pneumoniae B5055 were determined by serial passaging for 10 days in the absence of gentamicin (Figure 1 ). K. pneumoniae B5055 pBBR1MCS-5 showed high plasmid stability across the 10 day passages (i.e. 100 generations), whereas a gradual loss of the mcr-1 recombinant plasmid was observed, with only 50% of the population maintaining the mcr-1 recombinant plasmid after 6 day passage (i.e. 60 generations). This result suggests that in the absence of antibiotic selective pressure the maintenance of mcr-1 in the population was decreased.
Lipid A profiling
To confirm the role of mcr-1 in pEtN modification of lipid A, we next sought to investigate the lipid A profile of each K. pneumoniae strain by LC-MS (Figure 2 ). The MS analyses from all three strains showed two predominant peaks at m/z 1717. 25 14 ]acyls), and the loss of one phosphate group from the glucosamine. MS analysis of the lipid A structure of K. pneumoniae B5055 pmcr-1 revealed two additional peaks at m/z 1840.26 and 1868.29, representing the addition of a pEtN residue (Dm/z " !123) to the hexa-acylated lipid A molecules described earlier at m/z 1717.25 and 1745.28, respectively. 41 
Biological cost of mcr-1 in vitro and in vivo
Competition assays were performed to determine whether mcr-1 is associated with biological cost in K. pneumoniae ( Figure S1 , available as Supplementary data at JAC Online). In comparison with the parent strain, lower selection coefficients were observed in vitro for both strains carrying the vector alone and mcr-1. However, a significantly lower selection coefficient (P , 0.05) was observed for K. pneumoniae B5055 pmcr-1 in the in vitro study, compared with the strain carrying the vector alone (Figure 3) . This result showed a biological fitness cost incurred in vitro by harbouring mcr-1. It appeared that in the absence of polymyxin B the strain carrying the vector only showed a minor reduction in growth in the mouse thigh infection model (P " 0.34). In comparison, it is clearly evident that the growth of the strain carrying the plasmid harbouring mcr-1 was significantly reduced in the infected mouse thighs (Figure 4a ; P , 0.05). The impact of mcr-1 on polymyxin resistance in vivo was also illustrated using the same infection model but in the presence of polymyxin. After polymyxin B treatment (30 mg/kg/day), 10000-fold reduction in the bacterial viability was observed at 24 h for K. pneumoniae B5055 and K. pneumoniae B5055 pBBR1MCS-5 , compared with the untreated group, but only a Nang et al. Biological cost of mcr-1 in Klebsiella pneumoniae JAC 100-fold reduction for K. pneumoniae B5055 pmcr-1 (Figure 4b ; P , 0.05).
Discussion
The identification of mcr-1 as the first plasmid-borne polymyxin resistance gene prompted extensive and retrospective surveillance investigations across a range of Gram-negative species. 7,16 mcr-1 is commonly found in Gram-negative bacteria isolated from animals, humans and the environment globally. 7, 24 The primary aims of the present study were to investigate the impact of mcr-1 on polymyxin resistance and the fitness of mcr-1-carrying K. pneumoniae.
According to EUCAST, the breakpoint for polymyxin susceptibility in Enterobacteriaceae is defined as 2 mg/L. 42 When mcr-1 was introduced into K. pneumoniae B5055 via transformation with the recombinant plasmid (pmcr-1), the polymyxin B MIC increased from 1 to 4 mg/L (i.e. the polymyxin breakpoint for resistance). This moderate level of resistance has been demonstrated by other reports with bacterial isolates having MICs of 4-8 mg/L following experimental acquisition of mcr-1-carrying plasmids by polymyxin-susceptible E. coli strains via conjugation and transformation. 16, [43] [44] [45] [46] [47] [48] [49] Although the level of mcr-1-conferred polymyxin resistance is moderate, the ability of mcr-1 to improve bacterial survival in the presence of polymyxins was demonstrated in vivo using a neutropenic mouse thigh infection model. Similar findings were reported by Liu et al., 16 who showed that the presence of mcr-1 provided E. coli with adequate protection against colistin treatment in vivo. In order to exclude the possibility that the presence of other genetic elements in the plasmid contributed to the observed increase in polymyxin resistance, we also demonstrated that K. pneumoniae B5055 pBBR1MCS-5 (which carries only the vector) was susceptible to polymyxin treatment.
The evolution and persistence of antibiotic resistance in the bacterial population depends on a complex calculus factoring the biological fitness cost associated with the resistance and the impact of the resistance pressure; any significant fitness cost will allow a susceptible strain to outcompete the resistant strain in the absence of an antibiotic. 50 Variability in the fitness cost associated with antibiotic resistance can be attributed to various factors, including the mechanisms of resistance, bacterial species and antibiotic. A fitness cost has been shown to be associated with the acquisition of colistin resistance in Acinetobacter baumannii. 51, 52 Notably, the loss of LPS imposes a greater biological fitness cost in A. baumannii compared with modification of lipid A with pEtN. 53 However, not all mechanisms of polymyxin resistance carry a fitness cost; for example, no significant biological cost is associated with polymyxin resistance due to chromosomal inactivation of mgrB in K. pneumoniae. 54 The in vitro competition fitness assay and in vivo model from our study demonstrated that a significant biological cost was incurred when mcr-1 was introduced into K. pneumoniae in the absence of polymyxin treatment (Figures 3  and 4a) . It has been reported that travellers colonized by mcr-1-carrying bacteria were able to completely eliminate these bacteria a month after of returning to their home country. 55 This could suggest that mcr-1-carrying bacteria have reduced fitness in the K. pneumoniae B5055 pmcr-1 Figure 3 . Selection coefficient for K. pneumoniae B5055 parental strain, vector-only K. pneumoniae B5055 pBBR1MCS-5 strain and mcr-1-expressing K. pneumoniae B5055 pmcr-1 strain against the reference strain E. coli JW1. Error bars represent the standard deviation of the mean (n " 4). *P 0.05. Nang et al.
antibiotic-free environment. Another possibility is that loss of the mcr-1 gene from the bacteria is due to the instability of the mcr-1-harbouring plasmids in the absence of selective pressure. Our study found that plasmid stability in the absence of selective pressure was indeed reduced with the acquisition of mcr-1. The heavy usage of polymyxins in the veterinary and agriculture environment could act as the selective pressure that promotes the dissemination of mcr-1. The use of an artificial vector, pBBR1MCS-5, was a limitation of the present study. The vector itself showed a minor detrimental effect on the host bacteria in the absence of polymyxin treatment, but the mechanism is unknown. A recent study published after the submission of our manuscript showed that a negative fitness effect was correlated with both an artificial vector (pCR-Blunt II-TOPO) carrying mcr-1 and a native mcr-1 plasmid (pKP2442) in K. pneumoniae. 56 Unfortunately, a Galleria mellonella model, rather than rodents, was employed for measuring the in vivo fitness cost in this recent study. 56 Our present study employed a widely used mouse infection model, which is more clinically relevant, and demonstrated the negative influence of mcr-1 on in vivo fitness in K. pneumoniae.
In conclusion, our study demonstrates the beneficial effect of mcr-1 on the survival of K. pneumoniae in the presence of polymyxins. In the absence of selective pressure, mcr-1 negatively impacts the biological fitness of K. pneumoniae. It is likely that the spread of mcr-1 might be potentially attenuated by reducing polymyxin usage in both agriculture and healthcare sectors.
